clinical trial · NCT07389590
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Multiple SclerosisUblituximabOcrelizumab
brief summary
The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.
started
Feb 10, 2026
primary completion
Oct 1, 2028
completion
Mar 1, 2029
last updated
May 6, 2026
official title
A Pilot Study of Ublituximab in People With MS Experiencing Wearing Off Phenomena While Receiving Treatment With Ocrelizumab
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol